Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2025 Jul;45(7):431-433.
doi: 10.1007/s40261-025-01442-x. Epub 2025 May 9.

Comment on: "An Early Cost-Utility Model of mRNA-Based Therapies for the Treatment of Methylmalonic and Propionic Acidemia in the United Kingdom"

Sue Perera  1 , Geetanjoli Banerjee  2 , Vanja Sikirica  2 , Eliza Kruger  2 , Emily Combe  3 , Caroline Barwood  3 , Sofie Czarnota-Bojarski  3 , Stephanie Grunewald  4 , Sufin Yap  5
Affiliations
Comment

Comment on: "An Early Cost-Utility Model of mRNA-Based Therapies for the Treatment of Methylmalonic and Propionic Acidemia in the United Kingdom"

Sue Perera et al. Clin Drug Investig. 2025 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declarations. Funding: This work was funded by Moderna, Inc. Conflicts of Interest: SP, GB, VS and EK are employees of Moderna, Inc. EC, CB, and SCB are employees of FIECON, which is funded by Moderna, Inc. SG has served on an advisory board for Moderna, Inc. SY has received honoraria from Moderna, Inc. Ethics Approval: Not applicable. Consent to Participate: Not applicable. Consent for Publication: Not applicable. Availability of Data and Material: Not applicable. Code Availability: Not applicable. Author Contributions: All authors have contributed equally to the development of this commentary. All authors read and approved the final version of the commentary.

Comment on

References

    1. Bretos-Azcona PE, Wallace M, Jootun M, et al. An early cost-utility model of mRNA-based therapies for the treatment of methylmalonic and propionic acidemia in the United Kingdom. Clin Drug Investig. 2024;44:399–412. - PubMed
    1. Waisbren SE. Review of neuropsychological outcomes in isolated methylmalonic acidemia: recommendations for assessing impact of treatments. Metab Brain Dis. 2022;37:1317–35. - PubMed
    1. Baumgartner MR, Hörster F, Dionisi-Vici C, et al. Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia. Orphanet J Rare Dis. 2014;9:130. - PMC - PubMed
    1. Fujisawa D, Nakamura K, Mitsubuchi H, et al. Clinical features and management of organic acidemias in Japan. J Hum Genet. 2013;58:769–74. - PubMed
    1. Hörster F, Baumgartner MR, Viardot C, et al. Long-term outcome in methylmalonic acidurias is influenced by the underlying defect (mut0, mut−, cblA, cblB). Pediatr Res. 2007;62:225–30. - PubMed

LinkOut - more resources